COVID-19 therapies made from antibodies are often given to patients who are high risk of severe illness and hospitalization. But virologist and immunologist Michael Diamond, MD, PhD, at Washington University School of Medicine in St. Louis wanted to answer nagging questions about whether such antibody therapies retain their effectiveness against variants of the virus that causes COVID-19. So Diamond’s lab put the therapies to the test against the variants in animal models. In all, the researchers evaluated antibodies corresponding to the FDA-authorized ones made by Eli Lilly and Co., Regeneron and Vir Biotechnology/GlaxoSmithKline, as well as the antibodies that were under development and in clinical trials during study period by AbbVie, Vir and AstraZeneca. Many, but not all, dual antibody therapies made from combinations of two antibodies proved effective against a wide range of variants.
Subscribe now ➤ https://bit.ly/2NNQiyM
For more great content from the Higher Education Channel check us out at:
Facebook ➤ http://bit.ly/1WPZEek
Twitter ➤ http://bit.ly/22qZDNU
Instagram ➤ http://bit.ly/1THSOnM
0 Comments